Norfenfluramine

Source: Wikipedia, the free encyclopedia.
Norfenfluramine
Ball-and-stick model of the norfenfluramine molecule
Names
Preferred IUPAC name
1-[3-(Trifluoromethyl)phenyl]propan-2-amine
Other names
3-Trifluoromethylamphetamine
Identifiers
3D model (
JSmol
)
ChemSpider
IUPHAR/BPS
UNII
  • InChI=1S/C10H12F3N/c1-7(14)5-8-3-2-4-9(6-8)10(11,12)13/h2-4,6-7H,5,14H2,1H3 checkY
    Key: MLBHFBKZUPLWBD-UHFFFAOYSA-N checkY
  • InChI=1/C10H12F3N/c1-7(14)5-8-3-2-4-9(6-8)10(11,12)13/h2-4,6-7H,5,14H2,1H3
    Key: MLBHFBKZUPLWBD-UHFFFAOYAR
  • FC(F)(F)c1cccc(c1)CC(N)C
Properties
C10H12F3N
Molar mass 203.208 g·mol−1
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
checkY verify (what is checkY☒N ?)

Norfenfluramine, or 3-trifluoromethylamphetamine, is a never-marketed

cardiac fibroblasts on the tricuspid valve, known as cardiac fibrosis.[1] This side effect led to the withdrawal of fenfluramine as an anorectic agent worldwide, and to the withdrawal of benfluorex in Europe,[2] as both fenfluramine and benfluorex form norfenfluramine as an active metabolite. It is a human TAAR1 agonist.[3]

See also

References

  1. S2CID 30906680
    .
  2. ^ "European Medicines Agency recommends withdrawal of benfluorex from the market in European Union" (PDF). European Medicines Agency. 2009-12-18. Archived from the original (PDF) on 2009-12-22.
  3. PMID 22037049
    .